Capricor Therapeutics Inc (OQ:CAPR)

Mar 25, 2024 09:31 am ET
Thinking about buying stock in Curiositystream, Capricor Therapeutics, PowerFleet, Absci, or Nano-X Imaging?
NEW YORK, March 25, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CURI, CAPR, PWFL, ABSI, and NNOX.
Mar 21, 2024 08:30 am ET
Capricor Therapeutics to Present at Upcoming Investor Conferences
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases, today announced that the Company is scheduled to present at two upcoming...
Mar 06, 2024 08:30 am ET
Capricor Therapeutics Presents at 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases, announced today that the Company will present the positive 24-month...
Feb 29, 2024 04:05 pm ET
Capricor Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases, announced today its financial results for the fourth quarter and full...
Feb 27, 2024 08:30 am ET
Capricor Therapeutics Announces Upcoming Type-B Meeting with the FDA to Discuss Commercial Manufacturing Planning with an Aim to Expedite BLA Pathway for CAP-1002 in Duchenne Muscular Dystrophy
– Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases, announced today that the Company has been granted an in-person Type-B...
Feb 22, 2024 08:30 am ET
Capricor Therapeutics to Present Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Update on February 29
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases, will release its financial results for the fourth quarter and full year...
Feb 20, 2024 08:30 am ET
Capricor Therapeutics Announces Manufacturing Scale-Up of CAP-1002 Production at New San Diego Facility as it Continues Plans Toward Commercialization
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases, announced today the scale-up to expand manufacturing capacity of CAP-1002...
Jan 24, 2024 09:15 am ET
Capricor Therapeutics Announces Collaboration with the National Institutes of Health for Clinical Trial of Novel Exosome-Based Multivalent Vaccine for SARS-CoV-2
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases, today announced that Capricor’s proprietary StealthX™ exosome-based...
Dec 11, 2023 09:00 am ET
Capricor Therapeutics Announces Continuation of Phase 3 HOPE-3 Trial of CAP-1002 in Duchenne Muscular Dystrophy Based on Completion of Interim Futility Analysis
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, today announced a positive...
Nov 14, 2023 04:05 pm ET
Capricor Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, announced today its financial...
Nov 07, 2023 09:15 am ET
Capricor Therapeutics to Present Third Quarter 2023 Financial Results and Recent Corporate Update on November 14
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, will release its financial...
Oct 19, 2023 04:01 pm ET
Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar to Review Latest Developments of CAP-1002 Program
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, announced today that the Company...
Oct 10, 2023 09:00 am ET
Capricor Therapeutics Announces Late-Breaking Presentations at 28th Annual Congress of the World Muscle Society
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, today announced data from two...
Sep 29, 2023 07:35 am ET
Capricor Therapeutics Announces $23 Million Registered Direct Offering
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, today announced that it has...
Sep 29, 2023 07:30 am ET
Capricor Therapeutics Announces Positive Type-B Meeting with the FDA to Discuss Pathway to BLA for CAP-1002 in Duchenne Muscular Dystrophy
Company On Track to Complete HOPE-3 Enrollment and Report Outcome from Interim Analysis in Q4 2023- -Conference Call and Webcast Today at 8:30 a.m. ET- SAN DIEGO, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a...
Sep 06, 2023 09:00 am ET
Capricor Therapeutics Appoints Michael Kelliher to Board of Directors
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, today announced that the Company...
Aug 07, 2023 04:05 pm ET
Capricor Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, announced today its financial...
Aug 02, 2023 04:01 pm ET
Capricor Therapeutics to Present Second Quarter 2023 Financial Results and Recent Corporate Update on August 7
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, will release its financial...
Jul 24, 2023 08:30 am ET
Capricor Therapeutics Announces Appointment of Philip J. Gotwals, Ph.D. to its Board of Directors
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, today announced the appointment...
Jul 13, 2023 08:30 am ET
Capricor Therapeutics Announces Appointment of Paul Auwaerter, M.D. to its Board of Directors
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, today announced the appointment...
Jun 30, 2023 09:25 am ET
Capricor Therapeutics Announces Positive 24-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy
Safety and Efficacy Results Continue to Suggest Potential Disease Attenuation in Duchenne Muscular Dystrophy (DMD)- -Results to be Presented at the PPMD Annual Conference Being Held Today- SAN DIEGO, June 30, 2023 (GLOBE NEWSWIRE) -- Capricor...
Jun 13, 2023 09:15 am ET
Capricor Therapeutics to Present 24-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, today announced that the Company...
Jun 07, 2023 09:15 am ET
Capricor Therapeutics Announces Follow-up Type-B Clinical Meeting with the FDA for CAP-1002 for the Treatment of Duchenne Muscular Dystrophy
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, today announced an upcoming...
May 11, 2023 04:01 pm ET
Capricor Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, announced today its financial...
May 04, 2023 09:00 am ET
Capricor Therapeutics to Present First Quarter 2023 Financial Results and Recent Corporate Update on May 11
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, will release its financial...
Apr 27, 2023 09:00 am ET
Capricor Announces Peer-Reviewed Publication Demonstrating the Therapeutic Potential of Exosome-Based Multivalent Vaccine Developed from its StealthX™ Platform
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, announced today the publication...
Mar 23, 2023 09:25 am ET
Capricor Therapeutics Presents at 2023 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, announced today that the Company...
Mar 15, 2023 04:01 pm ET
Capricor Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, announced today its financial...
Mar 08, 2023 09:00 am ET
Capricor Therapeutics to Present Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Update on March 15
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, will release its financial...
Mar 02, 2023 09:15 am ET
Capricor Therapeutics Receives Clinical Research Forum’s 2023 Top Ten Clinical Research Achievement Award
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, announced today that the...
Feb 16, 2023 09:25 am ET
Capricor Therapeutics and Nippon Shinyaku Enter Partnership for Exclusive Commercialization and Distribution of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy in Japan
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, announced today that it has...
Jan 25, 2023 08:00 am ET
Capricor Therapeutics Announces Positive 18-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy Patients
Capricor to Host Webinar in Conjunction with Parent Project Muscular Dystrophy (PPMD) Today at 1:00 p.m. ET- SAN DIEGO, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of...
Jan 19, 2023 04:05 pm ET
Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar to Provide Recent Updates on CAP-1002 Program
Capricor Therapeutics (NASDAQ: CAPR) a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, announced today that the Company...
Jan 12, 2023 09:26 am ET
Capricor Announces Publication Highlighting New Advances for its Engineered Exosome Platform
Capricor Therapeutics (NASDAQ: CAPR) a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, announced today the publication of...
Nov 10, 2022 04:01 pm ET
Capricor Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, announced today its financial...
Nov 03, 2022 04:01 pm ET
Capricor Therapeutics to Present Third Quarter 2022 Financial Results and Recent Corporate Update on November 10
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, will release its financial...
Oct 06, 2022 09:00 am ET
Capricor Therapeutics to Present One-Year Results from HOPE-2 Open Label Extension Study at World Muscle Society 2022
Capricor Therapeutics (NASDAQ: CAPR) a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, announced today that the Company...
Sep 07, 2022 08:00 am ET
Capricor Therapeutics to Present at Upcoming Investor Conferences
Capricor Therapeutics (NASDAQ: CAPR) a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, announced today that the Company...
Aug 10, 2022 04:05 pm ET
Capricor Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, announced today its financial...
Aug 03, 2022 08:00 am ET
Capricor Therapeutics to Present Second Quarter 2022 Financial Results and Recent Corporate Update on August 10
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, will release its financial...
Jul 19, 2022 09:15 am ET
Capricor Therapeutics Announces First Patient Dosed in Pivotal Phase 3 Study of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, today announced commencement of...
Jun 27, 2022 07:00 am ET
Capricor Therapeutics Announces Statistically Significant Clinical Benefits in Skeletal Muscle Function in Non-Ambulant Duchenne Muscular Dystrophy Patients Treated with CAP-1002 in HOPE-2 Open Label
Results Suggest Disease Modification in DMD and Long-term Safety of CAP-1002- -Results were Presented at Late Breaking Session at PPMD’s Annual Conference on Saturday June 25, 2022- -Principal Investigator Dr. Craig McDonald and Capricor...
Jun 17, 2022 09:00 am ET
Capricor Therapeutics to Present One-Year Efficacy Results from its Ongoing HOPE-2 Open Label Extension Study at 2022 Parent Project Muscular Dystrophy Annual Conference
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, today announced that the Company will...
May 25, 2022 09:00 am ET
Capricor Therapeutics Appoints Xavier Avat as Chief Business Officer
Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, today announced that it has appointed...
May 18, 2022 09:00 am ET
Capricor Therapeutics to Present at the H.C. Wainwright Global Investment Conference
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, announced today that Dr. Linda Marbán,...
May 10, 2022 04:01 pm ET
Capricor Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, announced today its financial results...
May 03, 2022 08:30 am ET
Capricor Therapeutics to Present First Quarter 2022 Financial Results and Recent Corporate Update on May 10
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, will release its financial results for...
Mar 29, 2022 09:00 am ET
Capricor Therapeutics to Participate in the Cantor Fitzgerald Rare Orphan Disease Summit
Capricor Therapeutics (NASDAQ: CAPR) a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, announced today that Dr. Linda Marbán,...
Mar 28, 2022 08:30 am ET
Capricor Therapeutics Reports Topline Results from Phase 2 Exploratory INSPIRE Trial in Severe Hospitalized COVID-19 Patients
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics, announced today that its Phase 2, INSPIRE study evaluating a single-dose intravenous infusion of...
Mar 11, 2022 08:00 am ET
The Lancet Publishes Positive Results from Capricor Therapeutics’ Phase 2 Study Evaluating CAP-1002 in Late-Stage Duchenne Muscular Dystrophy
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, announced today that The Lancet, a...
Mar 10, 2022 04:01 pm ET
Capricor Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, announced today its financial results...
Mar 03, 2022 09:15 am ET
Capricor Therapeutics to Present Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Update on March 10
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, will release its financial results for...
Mar 02, 2022 09:00 am ET
Capricor Therapeutics Names Dr. Daniel Paulson as Vice President of Clinical Development
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, announced today the expansion of its...
Jan 25, 2022 01:58 pm ET
Nippon Shinyaku and Capricor Therapeutics Enter into an Exclusive Partnership for Commercialization and Distribution of CAP-1002 for the Treatment* of Duchenne Muscular Dystrophy in US
KYOTO, Japan, Jan. 25, 2022 /PRNewswire/ -- *NS Pharma Note: CAP-1002 is an investigational therapy and not approved in the US.
Jan 25, 2022 09:45 am ET
Thinking about buying stock in SoFi Technologies, Vinco Ventures, DiDi Global, Capricor Therapeutics, or ShiftPixy?
NEW YORK, Jan. 25, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SOFI, BBIG, DIDI, CAPR, and PIXY.
Jan 25, 2022 05:00 am ET
Capricor Therapeutics and Nippon Shinyaku Enter Partnership for Exclusive Commercialization and Distribution of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy in the U.S.
Capricor Therapeutics (NASDAQ: CAPR) (“Capricor” or “the Company”), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, announced...
Dec 13, 2021 09:15 am ET
Capricor Therapeutics Announces Key Updates on its Vaccine and Therapeutic Programs for COVID-19
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, today announced new updates on its...
Nov 12, 2021 09:15 am ET
Capricor’s CEO Dr. Linda Marbán to Serve as Keynote Speaker at TriLink Annual mRNA Day
Capricor Therapeutics (NASDAQ: CAPR) (“Capricor” or “the Company”), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, today...
Nov 09, 2021 04:05 pm ET
Capricor Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update
CAP-1002 – Capricor’s Cell Therapy Program for COVID-19 -Phase 2 INSPIRE Trial Enrollment Complete with 63 Patients Randomized- Capricor’s Engineered Exosomes Platform Technology-Completing Non-Clinical Studies for IND Submission--Pipeline...
Nov 03, 2021 07:30 am ET
SHAREHOLDER ALERT: Morris Kandinov Investigating FFIE, CAPR, COO, and SEMOX; Shareholders are Encouraged to Contact the Firm
National law firm Morris Kandinov is investigating the actions of the officers and board of directors of Future Intelligent Electric Inc., Capricor Therapeutics, Inc., The Cooper Companies, Inc., and Semper MBS Total Return Fund Class A.   If you...
Nov 02, 2021 04:05 pm ET
Capricor Therapeutics to Present Third Quarter 2021 Financial Results and Recent Corporate Update on November 9
Capricor Therapeutics (NASDAQ: CAPR) a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, will release its financial results for...
Sep 27, 2021 10:55 am ET
Thinking about buying stock in Naked Brand, Farmmi, Unique Fabricating, Aehr Test Systems, or Capricor Therapeutics?
NEW YORK, Sept. 27, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NAKD, FAMI, UFAB, AEHR, and CAPR.
Sep 24, 2021 08:31 am ET
Thinking about buying stock in Capricor Therapeutics, vTv Therapeutics, Li-Cycle Holdings, Predictive Oncology, or Rewalk Robotics?
NEW YORK, Sept. 24, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CAPR, VTVT, LICY, POAI, and RWLK.
Sep 24, 2021 07:00 am ET
Capricor Therapeutics Announces Positive Final Data From its Phase 2 HOPE-2 Trial in Patients with Duchenne Muscular Dystrophy Treated with CAP-1002
Capricor Therapeutics (NASDAQ: CAPR) (“Capricor” or “the Company”), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, announced...
Sep 22, 2021 04:05 pm ET
Capricor Therapeutics to Present at the Upcoming Investor and Industry Healthcare Conferences
Capricor Therapeutics (NASDAQ: CAPR) (“Capricor” or “the Company”), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, announced...
Sep 07, 2021 09:00 am ET
Capricor Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, announced today that Linda Marbán,...
Sep 02, 2021 08:30 am ET
Capricor Therapeutics to Present Final Data from HOPE-2 Trial with CAP-1002 in Duchenne Muscular Dystrophy at World Muscle Society 2021
Capricor Therapeutics (NASDAQ: CAPR) (“Capricor” or “the Company”), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, announced...
Aug 12, 2021 04:01 pm ET
Capricor Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, today reported its financial results...
Aug 05, 2021 09:00 am ET
Capricor Therapeutics to Present Second Quarter 2021 Financial Results and Recent Corporate Update on August 12
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, will release its financial results for...
Aug 04, 2021 08:00 am ET
Capricor Announces Joint Publication with the US Army Institute of Surgical Research for Cardiosphere-Derived Exosomes as a Potential Therapeutic for Shock
Capricor Therapeutics (“Capricor” or “the Company”) (NASDAQ: CAPR), a biotechnology company focused on developing transformative cell and exosome-based therapeutics for treating and preventing a broad spectrum of diseases, announced today the...
Jul 27, 2021 08:00 am ET
Capricor Therapeutics Announces the Appointment of Karimah Es Sabar to its Board of Directors
Capricor Therapeutics (“Capricor” or “the Company”) (NASDAQ: CAPR), a biotechnology company focused on developing transformative cell and exosome-based therapeutics for treating and preventing a broad spectrum of diseases, today announced the...
Jun 24, 2021 08:30 am ET
Thinking about buying stock in Arcus Biosciences, Capricor Therapeutics, Orphazyme, Sundial Growers, or Citius Pharmaceuticals?
NEW YORK, June 24, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for RCUS, CAPR, ORPH, SNDL, and CTXR.
Jun 23, 2021 08:30 am ET
Thinking about buying stock in ConforMIS, Citius Pharmaceuticals, Clover Health, Capricor Therapeutics, or Dare Bioscience?
NEW YORK, June 23, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CFMS, CTXR, CLOV, CAPR, and DARE.
Jun 17, 2021 09:00 am ET
Capricor Therapeutics to Present Findings from HOPE-2 Open-Label Extension Study at Parent Project Muscular Dystrophy (PPMD) 2021 Virtual Annual Conference
Capricor Therapeutics (“Capricor” or “the Company”) (NASDAQ: CAPR), a biotechnology company focused on developing transformative cell and exosome-based therapeutics for treating and preventing a broad spectrum of diseases, announced today that...
Jun 10, 2021 09:15 am ET
Capricor Therapeutics to Participate in BIO Digital 2021 Conference
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, announced today that the company will...
May 18, 2021 08:30 am ET
Capricor To Present Preclinical Data for Exosome-mRNA Vaccine for SARS-CoV-2 at the International Society for Extracellular Vesicles (ISEV) Annual Meeting
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell- and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, announced that the Company will...
May 13, 2021 04:05 pm ET
Capricor Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell- and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, today reported its financial results...
May 12, 2021 09:00 am ET
Capricor to Present at the American Society of Gene and Cell Therapy’s 24th Annual Meeting
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell- and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, announced today that Linda Marbán,...
May 06, 2021 08:30 am ET
Capricor Therapeutics to Present First Quarter 2021 Financial Results and Recent Corporate Update on May 13
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell- and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, will release its financial results for...
Apr 29, 2021 08:00 am ET
Capricor Therapeutics Signs Exclusive Worldwide License Agreement with Johns Hopkins University to Expand its Exosome Platform Technology Portfolio
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell- and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, today announced that it has signed an...
Mar 11, 2021 04:01 pm ET
Capricor Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell- and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, announced today its financial results...
Mar 09, 2021 09:15 am ET
Capricor Therapeutics Announces New Advances in Exosome-Mediated mRNA Delivery Platform
Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell- and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, in collaboration with...
Mar 04, 2021 09:00 am ET
Capricor Therapeutics to Present Fourth Quarter and Full Year 2020 Financial Results and Recent Corporate Update on March 11
Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company focused on the development of first-in-class cell- and exosome-based therapeutics for the treatment and prevention of a variety of diseases and disorders will release its financial...
Feb 01, 2021 09:15 am ET
Capricor Therapeutics Announces Development of Serology Test to Confirm Activity of SARS-CoV-2 Vaccines
Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class cell- and exosome-based therapeutics for the treatment and prevention of a variety of...
Jan 19, 2021 09:15 am ET
Capricor Therapeutics Announces Publication Demonstrating Methods for Enhanced Potency of Cardiosphere-Derived Exosomes
Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class cell- and exosome-based therapeutics for the treatment and prevention of a variety of...
Jan 12, 2021 09:05 am ET
Capricor Collaborates with Lonza for the Development of CAP-1002, its Cell Therapy Candidate for the Treatment of Duchenne Muscular Dystrophy and Other Indications
Capricor Therapeutics, (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of the first-in-class cell and exosome-based therapeutics for the treatment and prevention of serious diseases, and Lonza today announced that...
Jan 08, 2021 08:31 am ET
Thinking about buying stock in Capricor Therapeutics, Cardtronics, Clearside Biomedical, Ardelyx, or FuelCell Energy?
NEW YORK, Jan. 8, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CAPR, CATM, CLSD, ARDX, and FCEL.
Dec 29, 2020 09:15 am ET
Capricor Therapeutics Announces DSMB Recommendation to Continue Phase II INSPIRE Trial for Severe COVID-19 Patients
Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class cell- and exosome-based therapeutics for the treatment and prevention of a variety of...
Nov 24, 2020 07:30 am ET
Capricor Therapeutics Commences Dosing Patients in Phase 2 Trial of CAP-1002 in Patients with Severe COVID-19
Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class cell and exosome-based therapeutics for the treatment and prevention of a variety of...
Nov 12, 2020 04:01 pm ET
Capricor Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update
Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class cell and exosome-based therapeutics for the treatment and prevention of a variety of...
Nov 09, 2020 09:15 am ET
Capricor Therapeutics Announces Positive Preclinical Data for Multivalent Exosome-mRNA Vaccine For COVID-19
Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class cell- and exosome-based therapeutics for the treatment and prevention of a variety of...
Nov 05, 2020 09:00 am ET
Capricor Therapeutics to Present Third Quarter 2020 Financial Results and Recent Corporate Update on November 12
Capricor Therapeutics (NASDAQ: CAPR) a clinical-stage biotechnology company focused on the development of first-in-class cell and exosome-based therapeutics for the treatment and prevention of diseases, announced today, that it will release its...
Sep 23, 2020 09:25 am ET
Capricor Therapeutics to Present Results from the HOPE-2 Trial with CAP-1002 in Duchenne Muscular Dystrophy at the International World Muscle Society Virtual Congress 2020
Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class cell and exosome-based therapeutics for the treatment and prevention of diseases, announced today that the Company will...
Sep 10, 2020 09:15 am ET
Capricor Therapeutics to Present at H.C. Wainwright 22nd Annual Global Investment Conference
Capricor Therapeutics (“Capricor”) (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class cell and exosome-based therapeutics for the treatment and prevention of diseases, announced today that Linda...
Aug 31, 2020 05:00 pm ET
LD Micro 360 Companies Set to Present this Week
LOS ANGELES, CA / ACCESSWIRE / August 31, 2020 / LD Micro today announced the final list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.
Aug 31, 2020 09:00 am ET
Capricor Therapeutics to Present at The LD 500 Virtual Conference
LOS ANGELES, CA / ACCESSWIRE / August 31, 2020 / Capricor Therapeutics ("Capricor") (NASDAQ:CAPR), a clinical-stage biotechnology company focused on the development of first-in-class cell and exosome-based therapeutics for the treatment and prevention of diseases, today announced that it will be presenting at the LD 500 investor conference on Friday, September 4 at 9:20 AM ET / 6:20 AM PT. Linda Marbán, Ph.D, Chief Executive Officer, will be presenting to a live virtual audience.
Aug 25, 2020 09:15 am ET
Capricor Therapeutics Announces U.S. FDA Acceptance of its IND Application for a Phase 2 Clinical Trial of CAP-1002 in Patients with COVID-19
Capricor Therapeutics (“Capricor”) (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class cell and exosome-based therapeutics for the treatment and prevention of diseases, announced today that the U.S....
Aug 06, 2020 04:01 pm ET
Capricor Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update
Capricor Therapeutics (“Capricor”) (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class cell and exosome-based therapeutics for the treatment and prevention of diseases, announced today its financial...
Jul 30, 2020 09:15 am ET
Capricor Therapeutics to Present Second Quarter 2020 Financial Results and Recent Corporate Update on August 6
Capricor Therapeutics (NASDAQ: CAPR) a clinical-stage biotechnology company focused on the development of first-in-class cell and exosome-based therapeutics for the treatment and prevention of diseases, announced today that it will release its...
Jul 27, 2020 09:31 am ET
Thinking about buying stock in Riot Blockchain, Onconova Therapeutics, Capricor Therapeutics, Genocea Biosciences, or eMagin Corp?
NEW YORK, July 27, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for RIOT, ONTX, CAPR, GNCA, and EMAN.
Jul 21, 2020 09:31 am ET
Thinking about buying stock in Caesars Entertainment, Moleculin Biotech, Onconova Therapeutics, Capricor Therapeutics, or Diffusion Pharmaceuticals?
NEW YORK, July 21, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CZR, MBRX, ONTX, CAPR, and DFFN.
Jun 10, 2020 09:31 am ET
Thinking about buying stock in Lakeland Industries, Capricor Therapeutics, T2 Biosystems, Callon Petroleum, or TOP Ships?
NEW YORK, June 10, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for LAKE, CAPR, TTOO, CPE, and TOPS.
Jun 04, 2020 09:15 am ET
Capricor to Participate in BIO Digital International Convention
Capricor Therapeutics (“Capricor”) (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment and prevention of diseases, announced today that it will be...
May 26, 2020 09:25 am ET
Capricor to Participate in Maxim Group's COVID-19 Virtual Conference Series on May 27, 2020
Capricor Therapeutics (“Capricor”) (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment and prevention of diseases, announced today that Capricor’s CEO, Linda...
May 14, 2020 04:01 pm ET
Capricor Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update
COVID-19 Program -COVID-19 Compassionate Use Case Series Published in Peer Reviewed Journal- -Reported 100 Percent Survival in Critical COVID-19 Patients Treated with CAP-1002 Under Compassionate Use Pathway- -Expanded Access Protocol Approved by...
May 13, 2020 04:30 pm ET
Capricor Therapeutics to Present First Quarter 2020 Financial Results and Recent Corporate Update on May 14
Capricor Therapeutics (“Capricor”) (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment and prevention of diseases, today announced that it will release its...
May 13, 2020 09:31 am ET
Thinking about buying stock in Capricor Therapeutics, Waitr, Takeda Pharmaceutical, Sorrento Therapeutics, or Inovio Pharmaceuticals?
NEW YORK, May 13, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CAPR, WTRH, TAK, SRNE, and INO.
May 13, 2020 07:00 am ET
Capricor Announces Positive Top-Line Final Results from HOPE-2 Study in Patients with Duchenne Muscular Dystrophy Treated with Lead Candidate CAP-1002
First Ever Study in DMD that Correlates Stabilization in Cardiac Function with a Reduction in a Biomarker of Cell Damage- -Company Planning to Meet with FDA to Discuss Pathway to Approval- -To Host Conference Call and Webcast Today at 8AM ET-...
May 04, 2020 09:31 am ET
Thinking about buying stock in Applied DNA Sciences, Agile Therapeutics, Canopy Growth Corp, Fluidigm Corp, or Capricor Therapeutics?
NEW YORK, May 4, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for APDN, AGRX, CGC, FLDM, and CAPR.
Apr 29, 2020 11:00 am ET
Thinking about buying stock in Capricor Therapeutics, NXT-ID Inc, Brinker International, AMC Entertainment, or Biondvax Pharmaceuticals?
NEW YORK, April 29, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CAPR, NXTD, EAT, AMC, and BVXV.
Apr 29, 2020 09:15 am ET
New Capricor Data Reports 100 Percent Survival in Critical COVID-19 Patients Treated with CAP-1002
Capricor Therapeutics (“Capricor”) (NASDAQ: CAPR) a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment and prevention of diseases, announced today new data reporting 100...
Apr 13, 2020 09:00 am ET
Capricor Therapeutics to Host Key Opinion Leader Call on Cardiac Complications of Duchenne Muscular Dystrophy
Capricor Therapeutics (NASDAQ: CAPR) a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment or prevention of serious diseases, today announced that it will host a Key Opinion...
Apr 03, 2020 09:31 am ET
Thinking about buying stock in Capricor Therapeutics, Chesapeake Energy Corp, electroCore, General Motors, or MGM Resorts?
NEW YORK, April 3, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CAPR, CHK, ECOR, GM, and MGM.
Apr 03, 2020 08:00 am ET
Capricor Initiates Compassionate Use Program for Severe COVID-19 Patients using CAP-1002, its Novel Cell Therapy
Capricor Therapeutics (NASDAQ: CAPR) a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment or prevention of serious diseases, today announced it is providing CAP-1002, its...
Mar 24, 2020 08:00 am ET
Capricor Therapeutics to Host a Key Opinion Leader Call On Why Exosomes are Uniquely Suited for Vaccine Development
Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy (DMD) and other rare disorders, today announced that...
Mar 18, 2020 04:01 pm ET
Capricor Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy (DMD) and other rare disorders, today announced its...
Mar 17, 2020 08:00 am ET
Capricor Therapeutics Announces Strategic Plan for Exosome Platform Technology Products Expansion
Capricor Therapeutics (NASDAQ: CAPR) a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy (DMD) and other rare disorders, today announced the...
Mar 11, 2020 04:30 pm ET
Capricor Therapeutics to Present Fourth Quarter and Full Year 2019 Financial Results and Recent Corporate Update on March 18
Capricor Therapeutics (NASDAQ: CAPR) a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy and other rare disorders will release its financial...
Dec 19, 2019 01:14 pm ET
Capricor Therapeutics Announces Closing of $5.1 Million Offering Priced At-the-Market
Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy and other rare disorders, today announced the...
Dec 17, 2019 01:52 pm ET
Capricor Therapeutics Announces Pricing of $5.1 Million Offering Priced At-the-Market
Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy and other rare disorders, today announced that...
Nov 07, 2019 04:00 pm ET
Capricor Therapeutics Reports Third Quarter 2019 Financial Results and Provides Recent Corporate Update
Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy (DMD) and other rare disorders, today announced its...
Nov 01, 2019 09:00 am ET
Capricor Therapeutics to Present Third Quarter 2019 Financial Results and Recent Corporate Update on November 7
Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy and other rare disorders, will report its third...
Oct 21, 2019 09:25 am ET
Capricor Therapeutics to Host Key Opinion Leader Call on the Role of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy (DMD)
Capricor Therapeutics (Nasdaq: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy (DMD) and other rare disorders, announced today that...
Oct 07, 2019 06:30 am ET
Capricor Presents Additional Positive Data from Ongoing HOPE-2 Study of CAP-1002 in Duchenne Muscular Dystrophy at World Muscle Society: Data Demonstrates Improved PUL 2.0 Performance at 6 Months
Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company, in its presentation at the 24th Annual International Congress of the World Muscle Society, presented additional six-month interim data from HOPE-2, its ongoing...
Oct 02, 2019 09:15 am ET
Capricor to Present Interim Results from the HOPE-2 Trial in a Late Breaking Session of the World Muscle Society and Company to Host Conference Call Monday, October 7 at 5:30 AM PT / 8:30 AM ET
Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy (DMD) and other rare disorders, announced that it...
Sep 24, 2019 07:30 am ET
Capricor Therapeutics to Meet with FDA to Discuss CAP-1002 to Treat Duchenne Muscular Dystrophy
Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy (DMD) and other rare disorders, announced today that...
Sep 17, 2019 09:31 am ET
Thinking about buying stock in Aclaris Therapeutics, Alder Biopharmaceuticals, Capricor Therapeutics, Canopy Growth, or ConocoPhillips?
NEW YORK, Sept. 17, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACRS, ALDR, CAPR, CGC, and COP.
Sep 17, 2019 07:00 am ET
Capricor Therapeutics to Present Results from the HOPE-2 Trial of CAP-1002 in Duchenne Muscular Dystrophy in a Late Breaking Session of the World Muscle Society
Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy (DMD) and other rare disorders, today announced that...
Sep 06, 2019 07:30 am ET
Capricor Therapeutics to Present at Upcoming Conferences
Capricor Therapeutics (NASDAQ: CAPR),  a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy and other rare disorders, today announced that that...
Aug 06, 2019 04:00 pm ET
Capricor Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update
Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy and other rare disorders, today announced its...
Jul 30, 2019 08:00 am ET
Capricor Therapeutics to Present Second Quarter 2019 Financial Results and Recent Corporate Update on August 6
Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy and other rare disorders, will report its second...
Jul 25, 2019 07:00 am ET
Capricor Therapeutics Announces Positive DSMB Safety and Futility Review and Continuation of its HOPE-2 Study in Duchenne Muscular Dystrophy
Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company, today announced that its independent Data and Safety Monitoring Board (DSMB) completed its safety assessment and futility analysis review of the company’s ongoing...
Jul 17, 2019 07:00 am ET
Capricor Therapeutics and Parents Project Muscular Dystrophy to Host Webinar to Discuss Interim Analysis of the HOPE-2 Clinical Trial to Treat Patients with Duchenne Muscular Dystrophy
Capricor Therapeutics, Inc. (NASDAQ: CAPR) announced positive results from its interim analysis in the HOPE-2 Trial on Monday. The public is invited to join Parent Project Muscular Dystrophy Founding President and CEO Pat Furlong and Capricor...
Jul 15, 2019 09:31 am ET
Thinking about buying stock in Aurora Cannabis, Capricor Therapeutics, China Lending Corp., JPMorgan Chase, or Energy Fuels?
NEW YORK, July 15, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACB, CAPR, CLDC, JPM, and UUUU.
Jul 15, 2019 06:00 am ET
Capricor Therapeutics Announces Positive Results from its Interim Analysis in the HOPE-2 Trial to Treat Patients with Duchenne Muscular Dystrophy
Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company, today announced that a pre-specified interim analysis performed on 6-month data from the HOPE-2 trial showed statistically significant results across several...
May 13, 2019 04:00 pm ET
Capricor Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update
Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy and other rare disorders, today announced its...
May 06, 2019 04:00 pm ET
Capricor Therapeutics to Present First Quarter 2019 Financial Results and Recent Corporate Update on May 13
Capricor Therapeutics (NASDAQ: CAPR),  a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy and other rare disorders, will report its first...
Apr 19, 2019 07:15 am ET
Investor Expectations to Drive Momentum within Workhorse Group, TRACON Pharmaceuticals, Capricor Therapeutics, Nuverra Environmental Solutions, Milestone Scientific, and Socket Mobile — Discovering Un
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Workhorse Group, Inc. (NASDAQ:WKHS), TRACON Pharmaceuticals, Inc....
Mar 28, 2019 04:00 pm ET
Capricor Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy and other rare disorders, today announced its...
Mar 21, 2019 08:00 am ET
Capricor Therapeutics to Present Fourth Quarter and Full Year 2018 Financial Results and Recent Corporate Update on March 28
Capricor Therapeutics (NASDAQ: CAPR),  a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy and other rare disorders, will report its fourth...
Feb 06, 2019 07:00 am ET
Capricor Resumes Dosing of Enrolled Patients in HOPE-2 Clinical Trial for Duchenne Muscular Dystrophy
Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company, today announced that it has resumed per protocol dosing of patients already enrolled in its HOPE-2 clinical trial of CAP-1002, the company’s novel cell therapy candidate...
Jan 24, 2019 07:00 am ET
Neurology Publishes Study Reporting Significant Improvements in Duchenne Muscular Dystrophy Patients Treated with Capricor’s Novel Cell Therapy
Neurology®, an international peer-reviewed journal, on Wednesday published the results of the HOPE-Duchenne clinical trial that evaluated the safety and efficacy of a single intracoronary dose of Capricor Therapeutics’ (NASDAQ: CAPR) novel cell...
Jan 22, 2019 07:00 am ET
Capricor Announces Positive Outcomes from Comprehensive Multidisciplinary Meeting with FDA
Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company, today announced that it had positive outcomes in its comprehensive multidisciplinary meeting with the U.S. Food and Drug Administration (FDA) regarding development of the...
Dec 27, 2018 07:25 am ET
Factors of Influence in 2019, Key Indicators and Opportunity within Halozyme Therapeutics, Capricor Therapeutics, Appian, Yext, Agile Therapeutics, and Corbus Pharmaceuticals — New Research Emphasizes
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Halozyme Therapeutics, Inc. (NASDAQ:HALO), Capricor Therapeutics, Inc....
Nov 28, 2018 08:35 am ET
Research Report Identifies OraSure Technologies, Sierra Wireless, Seres Therapeutics, Lydall, ChromaDex, and Capricor Therapeutics with Renewed Outlook — Fundamental Analysis, Calculating Forward Move
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of OraSure Technologies, Inc. (NASDAQ:OSUR), Sierra Wireless, Inc....
Nov 13, 2018 04:01 pm ET
Capricor Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update
Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy and other rare disorders, today announced its...
Nov 12, 2018 07:00 am ET
Capricor to Meet with FDA under its RMAT Designation to Discuss HOPE-2 Clinical Trial
Capricor Therapeutics (NASDAQ: CAPR) announced today that it will meet with the U.S. Food and Drug Administration (FDA) in December to discuss clinical trial design, surrogate or intermediate endpoints and manufacturing processes for CAP-1002,...
Nov 08, 2018 07:00 am ET
Capricor Therapeutics to Present Corporate Overview and Poster at Action Duchenne International Conference
During the Action Duchenne International Conference, Capricor Therapeutics, Inc. (NASDAQ: CAPR) will present a corporate update on its Duchenne muscular dystrophy program and a poster reporting on a pre-clinical study of its exosome-based therapy....
Nov 06, 2018 07:00 am ET
Capricor Therapeutics to Present Third Quarter Financial Results and Corporate Update on November 13
Capricor Therapeutics (NASDAQ: CAPR),  a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy and other rare disorders, will report its third...
Nov 02, 2018 07:00 am ET
Capricor Therapeutics to Provide Corporate Update at BIO-Europe Conference on Nov. 6
Capricor Therapeutics, Inc. (NASDAQ: CAPR) will provide a corporate overview of its research and development of cell and exosome-based therapies for Duchenne muscular dystrophy and other rare diseases during the BIO-Europe® 24th Annual...
Oct 22, 2018 07:00 am ET
Capricor Therapeutics to Participate in Upcoming Conferences  
Linda Marbán, Ph.D, CEO of Capricor Therapeutics, Inc. (NASDAQ: CAPR), is presenting at two conferences, the BTIG Fall Biotechnology Conference on Thursday in New York and the American Society of Exosomes and Microvesicles Annual Meeting, which...
Oct 17, 2018 09:00 am ET
Market Trends Toward New Normal in Halozyme Therapeutics, Fitbit, Iconix Brand Group, Leap Therapeutics, LightPath Technologies, and Capricor Therapeutics — Emerging Consolidated Expectations, Analyst
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Halozyme Therapeutics, Inc. (NASDAQ:HALO), Fitbit, Inc. (NYSE:FIT),...
Oct 03, 2018 07:00 am ET
Capricor Therapeutics to Present at 2018 Cell & Gene Meeting on the Mesa
Capricor Therapeutics, Inc. (NASDAQ: CAPR) will provide a presentation at the 2018 Cell Gene Meeting on the Mesa today on its cell therapy, CAP-1002, which is currently in clinical development for the treatment of Duchenne muscular dystrophy. It...
Aug 23, 2018 07:50 am ET
New Research Coverage Highlights Live Nation Entertainment, LightPath Technologies, Synchronoss Technologies, Mallinckrodt public limited company, Capricor Therapeutics, and Mersana Therapeutics — Con
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Live Nation Entertainment, Inc. (NYSE:LYV), LightPath Technologies, Inc....
Aug 21, 2018 07:00 am ET
Capricor Therapeutics Presents Results of Studies of CAP-2003 at Gordon Research Conference on Extracellular Vesicles
At the Gordon Research Conference on Extracellular Vesicles in Newry, Maine, Capricor Therapeutics (NASDAQ: CAPR) presented research findings on the mechanism of action and the immunomodulatory capacities of CAP-2003, the company’s investigational...
Aug 09, 2018 04:00 pm ET
Capricor Therapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update
Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy and other rare disorders, today announced its...
Aug 02, 2018 04:00 pm ET
Capricor Therapeutics to Present Second Quarter Financial Results and Corporate Update on August 9
Capricor Therapeutics (NASDAQ:CAPR),  a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy and other rare disorders, will report its second...
Jul 17, 2018 07:00 am ET
Capricor and USAISR Announce Collaboration to Investigate Exosome Platform to Treat Injured Troops
Capricor Therapeutics (NASDAQ:CAPR) today announced it has entered into an agreement with the U.S. Army Institute of Surgical Research (USAISR) to study the potential for the company’s next-generation investigational therapeutic platform,...
Jul 13, 2018 09:00 am ET
Capricor Therapeutics and PPMD to Host Webinar for Duchenne Muscular Dystrophy Community on July 18
Capricor Therapeutics (NASDAQ:CAPR) and Parent Project Muscular Dystrophy (PPMD) will host a webinar at 1 p.m. ET on July 18 to provide information about the HOPE-2 clinical trial, which is evaluating the safety and efficacy of repeat doses of...
Jun 28, 2018 07:00 am ET
Capricor Therapeutics to Present at PPMD Annual Conference
Capricor Therapeutics’ (NASDAQ:CAPR) chief medical officer, Deborah Ascheim, M.D., will present a corporate overview at the Parents Project Muscular Dystrophy (PPMD) 2018 Annual Conference on June 29 in Scottsdale, AZ. PPMD 2018 Annual Conference...
Jun 13, 2018 07:35 am ET
Detailed Research: Economic Perspectives on CarGurus, ArcelorMittal, Capricor Therapeutics, B&G Foods, Ionis Pharmaceuticals, and Photronics — What Drives Growth in Today's Competitive Landscape
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of CarGurus, Inc. (NASDAQ:CARG), ArcelorMittal (NYSE:MT), Capricor...
May 29, 2018 07:00 am ET
Capricor Therapeutics to Present at the 2018 BIO International Convention in Boston
Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing biological therapies for Duchenne muscular dystrophy and other rare disorders, today announced that Linda Marbán, Ph.D., its president and chief executive officer, is scheduled...
May 10, 2018 04:00 pm ET
Capricor Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update
Capricor Therapeutics (NASDAQ:CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy and other rare disorders, today announced its...
May 04, 2018 08:00 am ET
Capricor Therapeutics to Present First Quarter 2018 Financial Results and Corporate Update on May 10
Capricor Therapeutics (NASDAQ:CAPR),  a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy and other rare disorders, will report its first...
May 03, 2018 07:00 am ET
Capricor to Present on Exosomes at the Plenary Session of the International Society for Cellular Therapy in Montreal
Capricor Therapeutics (NASDAQ:CAPR) today announced that  Linda Marbán, Ph.D., Capricor president and CEO, will provide a presentation on exosomes at the plenary session of the International Society for Cellular Therapy (ISCT) 2018 Montreal Annual...
Apr 30, 2018 07:00 am ET
Capricor Announces Initiation of HOPE-2 Clinical Trial of CAP-1002 for Duchenne Muscular Dystrophy
UC Davis Medical Center First Site in Nation to Enroll and Treat Participants
Apr 12, 2018 07:00 am ET
Capricor to Provide Presentation at the Alliance for Regenerative Medicine’s Investor Day
LOS ANGELES, April 12, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR) today announced that it will be among the companies providing presentations at the Alliance for Regenerative Medicine’s (ARM’s) annual Cell & Gene Therapy Investor Day on April...
Apr 06, 2018 10:00 am ET
Capricor Therapeutics to Present at the MicroCap Conference on April 9, 2018
LOS ANGELES, CA / ACCESSWIRE / April 6, 2018 / Capricor Therapeutics (NASDAQ: CAPR) today announces that AJ Bergmann, Chief Financial Officer will be a featured presenter at the MicroCap Conference on Monday, April 9, 2018 at 11:30 AM Eastern Time. The conference is being held at the Essex House in New York City.
Mar 21, 2018 07:00 am ET
Capricor Therapeutics to Present at Upcoming Oppenheimer and Needham Healthcare Conferences
LOS ANGELES, March 21, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR) today announced that it will participate in two upcoming investment banking conferences, Oppenheimer’s 28th Annual Healthcare Conference and the Needham & Company 17th Annual Healthcare Conference in...
Mar 14, 2018 04:00 pm ET
Mar 08, 2018 04:00 pm ET
Feb 28, 2018 08:00 am ET
Capricor to Host Key Opinion Leader Lunch on March 9
Leading Researchers and Advocate for Duchenne Muscular Dystrophy to Discuss Emerging Paradigms in Treating the Disease
Feb 23, 2018 08:00 am ET
Report: Developing Opportunities within Tupperware Brands, Eaton Vance, Marcus & Millichap, Lockheed Martin, Coherus BioSciences, and Capricor Therapeutics — Future Expectations, Projections Moving in
NEW YORK, Feb. 23, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Tupperware Brands Corporation (NYSE:TUP), Eaton Vance...
Feb 22, 2018 01:23 pm ET
New Published Study Reports Cardiosphere-Derived Cells Improved Skeletal and Cardiac Muscle Function in Mouse Model of Duchenne Muscular Dystrophy
Cedars-Sinai Researchers Say Findings Lay Groundwork for Testing of CAP-1002 in Patients with Duchenne Muscular Dystrophy
Feb 05, 2018 11:11 am ET
Jan 16, 2018 07:00 am ET
Capricor Announces Licensing of Additional Patent Applications from Cedars-Sinai Medical Center for Cellular and Exosome-based Technologies
New Patent Applications Pave Way for Capricor to Develop Potential New Therapeutic Platforms for Duchenne Muscular Dystrophy and other Disorders
Dec 18, 2017 08:00 am ET
Market Trends Toward New Normal in Lockheed Martin, Silver Spring Networks, Capricor Therapeutics, Tupperware Brands, Eaton Vance, and Marcus & Millichap — Emerging Consolidated Expectations, Analyst
NEW YORK, Dec. 18, 2017 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Lockheed Martin Corporation (NYSE:LMT), Silver Spring...
Dec 13, 2017 07:00 am ET
Capricor Therapeutics Announces Issuance of Key U.S. Patent on Exosome Technology
LOS ANGELES, Dec. 13, 2017 /PRNewswire/ -- Capricor Therapeutics (NASDAQ: CAPR) today announced that the U.S. Patent and Trademark Office has issued U.S. Patent  9,828,603, which includes composition of matter claims covering cardiosphere-derived cell exosomes. This patent, entitled "Exosomes and Micro-ribonucleic Acids for Tissue Regeneration," is expected to run until at least 2033.
Nov 29, 2017 06:00 am ET
Capricor Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for CAP-1002
LOS ANGELES, Nov. 29, 2017 /PRNewswire/ -- Capricor Therapeutics (NASDAQ: CAPR) today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to conduct a new clinical trial of CAP-1002, its lead investigational therapy, in boys and young men in advanced stages of Duchenne muscular dystrophy, a fatal genetic disorder for which there are limited treatment options.
Nov 22, 2017 06:00 am ET
Capricor Therapeutics to Present at the Piper Jaffray Healthcare Conference
LOS ANGELES, Nov. 22, 2017 /PRNewswire/ -- Capricor Therapeutics (NASDAQ: CAPR) announced that Linda Marbán, Ph.D., president and CEO, will present at the Piper Jaffray Healthcare Conference in New York on Wednesday, November 29, 2017 at 11:50 a.m. ET.
Nov 15, 2017 12:00 pm ET
Significant Improvements Reported in Duchenne Muscular Dystrophy Patients Treated with Capricor's Investigational Cell Therapy
ANAHEIM, Calif., Nov. 15, 2017 /PRNewswire/ -- Boys and young men in advanced stages of Duchenne muscular dystrophy experienced significant and sustained improvements in cardiac structure and function, as well as skeletal muscle function, following treatment with CAP-1002, the lead investigational therapy under development at Capricor Therapeutics (NASDAQ: CAPR). These findings were reported today by Ronald G. Victor, M.D. at a Late-Breaking Science session of the American Heart Association Scientific Sessions 2017.
Nov 13, 2017 08:30 am ET
New Research Coverage Highlights Leucadia National, Matador Resources, Bemis Company, Capricor Therapeutics, IZEA, and Comcast – Consolidated Revenues, Company Growth, and Expectations for 2018
NEW YORK, Nov. 13, 2017 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Leucadia National Corporation (NYSE:LUK), Matador Resources...
Nov 08, 2017 04:01 pm ET
Capricor Therapeutics Reports Third Quarter 2017 Financial Results and Provides Update on Duchenne Muscular Dystrophy Development Program
LOS ANGELES, Nov. 8, 2017 /PRNewswire/ -- Capricor Therapeutics, Inc. (NASDAQ: CAPR) today announced its financial results for the third quarter ended September 30, 2017 and provided an update on its development of CAP-1002 for the treatment of Duchenne muscular dystrophy (DMD).
Nov 01, 2017 05:30 pm ET
Capricor Therapeutics Third Quarter 2017 Update Webcast and Conference Call Scheduled for Wednesday, November 8
LOS ANGELES, Nov. 1, 2017 /PRNewswire/ -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing biological therapies for Duchenne muscular dystrophy and other rare diseases, will report third quarter 2017 financial results shortly after the NASDAQ market close on Wednesday, November 8, 2017. Management will then host a webcast and conference call at 4:30 p.m. ET.
Oct 25, 2017 08:00 am ET
Capricor Announces 12-Month Results from HOPE-1 Trial in Duchenne Muscular Dystrophy to be Presented at AHA Late-Breaking Session
LOS ANGELES, Oct. 25, 2017 /PRNewswire/ -- Capricor Therapeutics, Inc. (NASDAQ: CAPR) today announced that the American Heart Association (AHA) Scientific Sessions 2017 has accepted for presentation at a late-breaking session the 12-month results from the company's HOPE-1 clinical trial of its lead investigational product, CAP-1002, in boys and young men in advanced stages of Duchenne muscular dystrophy.
Oct 06, 2017 10:00 am ET
Capricor Therapeutics Reports Intravenous Administration of CAP-1002 Shown to be Effective in Preclinical Models of Duchenne Muscular Dystrophy
LA JOLLA, Calif., Oct. 6, 2017 /PRNewswire/ -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), in a poster presentation at the Alliance for Regenerative Medicine's Cell and Gene Meeting on the Mesa, provided data which support the peripheral intravenous (IV) administration method the company plans to use in HOPE-2, its planned next clinical trial of its lead investigational product, CAP-1002, for the treatment of Duchenne muscular dystrophy (DMD).
Oct 04, 2017 08:00 am ET
Capricor Therapeutics Presents Positive Six-Month Results in Duchenne Muscular Dystrophy at World Muscle Society International Congress
SAINT MALO, France, Oct. 4, 2017 /PRNewswire/ -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), in its presentation today at the 22nd Annual International Congress of the World Muscle Society, reported that teens and young men in the advanced stages of Duchenne muscular dystrophy (DMD) experienced meaningful improvements in cardiac and upper limb function after a single dose of Capricor's lead investigational product, CAP-1002. DMD is a rare, life-threatening genetic disorder for which treatment options are limited.
Sep 26, 2017 08:00 am ET
Capricor Therapeutics Advances Clinical Development Program in Duchenne Muscular Dystrophy with Naming of Principal Investigator
LOS ANGELES, Sept. 26, 2017 /PRNewswire/ -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), which is developing biological therapies for Duchenne muscular dystrophy (DMD) and other rare diseases, today announced that the national principal investigator for its HOPE-2 Trial will be Craig M. McDonald, M.D., a distinguished thought leader in the clinical management of neuromuscular diseases, including muscular dystrophies, and the development of novel outcome measures for DMD clinical trials.
Sep 18, 2017 08:00 am ET
Capricor Therapeutics to Present Six-Month Results from the Randomized HOPE Trial of CAP-1002 in Duchenne Muscular Dystrophy in a Late Breaking Session of the World Muscle Society
LOS ANGELES, Sept. 18, 2017 /PRNewswire/ -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing biological therapies for Duchenne muscular dystrophy (DMD) and other rare diseases, today announced that it will present six-month follow-up results from the randomized Phase I/II HOPE-Duchenne clinical trial of CAP-1002 in boys and young men with Duchenne muscular dystrophy (DMD) at the 22nd International Congress of the World Muscle Society. The late breaking abstract and results will be presented in the late breaking poster session starting at 10:30am CEST on Wednesda
Aug 10, 2017 05:05 pm ET
Capricor Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update
LOS ANGELES, Aug. 10, 2017 /PRNewswire/ -- Capricor Therapeutics, Inc. (NASDAQ: CAPR) today announced its financial results for the second quarter ended June 30, 2017 and provided an update on its business.
Aug 03, 2017 05:05 pm ET
Capricor Therapeutics Second Quarter 2017 Update Webcast and Conference Call Scheduled for Thursday, August 10
LOS ANGELES, Aug. 3, 2017 /PRNewswire/ -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing biological therapies for Duchenne muscular dystrophy and other rare diseases, will report second quarter 2017 financial results shortly after the NASDAQ market close on Thursday, August 10, 2017. Management will then host a webcast and conference call at 4:30 p.m. ET.
Jul 27, 2017 07:00 am ET
Capricor Announces Results of FDA Meeting on Intravenous CAP-1002 for Duchenne Muscular Dystrophy
LOS ANGELES, July 27, 2017 /PRNewswire/ -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing biological therapies for Duchenne muscular dystrophy (DMD) and other rare diseases, today announced that it has received official minutes of the meeting held recently between the U.S. Food and Drug Administration (FDA) and Capricor to discuss the development of intravenous CAP-1002 (allogeneic cardiosphere-derived cells) for the treatment of Duchenne muscular dystrophy (DMD).
Jul 18, 2017 09:00 am ET
Capricor Receives Rare Pediatric Disease Designation from FDA for CAP-1002 for Patients with Duchenne Muscular Dystrophy
LOS ANGELES, July 18, 2017 /PRNewswire/ -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing biological therapies for Duchenne muscular dystrophy and other rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to CAP-1002, Capricor's development candidate for the treatment of Duchenne muscular dystrophy, a debilitating genetic disorder characterized by progressive weakness and chronic inflammation of skeletal, heart, and respiratory muscles. The Rare Pediatric Disease Designation, as well as
Jul 06, 2017 07:30 pm ET
Capricor Therapeutics Retains Full Rights to CAP-1002 as Janssen Biotech, Inc. Decides Not to Exercise Option
LOS ANGELES, July 6, 2017 /PRNewswire/ -- Capricor Therapeutics, Inc. (NASDAQ: CAPR) today announced that Janssen Biotech, Inc. (Janssen) has decided not to exercise its option to exclusively license Capricor's lead candidate CAP-1002 (allogeneic cardiosphere-derived cells) for development and commercialization in the field of cardiology. In connection with this decision, the Collaboration Agreement and License Option entered into between Capricor and Janssen has been terminated. As a result, Capricor shall retain all rights to develop and commercialize CAP-1002 for any indication, either in
Jun 29, 2017 10:00 am ET
Six-Month Results from Capricor's HOPE-Duchenne Trial to be Presented at the 2017 PPMD Annual Connect Conference
LOS ANGELES, June 29, 2017 /PRNewswire/ -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing biological therapies for Duchenne muscular dystrophy and other disorders, will present interim six-month safety and efficacy results from its Phase I/II HOPE-Duchenne clinical trial of CAP-1002 (allogeneic cardiosphere-derived cells) on a poster to be featured at the 2017 Parent Project Muscular Dystrophy (PPMD) Annual Connect Conference. The conference, which starts today and will run through July 2, is being held at the Chicago Marriott Downtown hotel in Chicago, Illino
Jun 15, 2017 03:00 pm ET
Capricor Therapeutics to Present at 2017 BIO International Convention
LOS ANGELES, June 15, 2017 /PRNewswire/ -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing biological therapies for Duchenne muscular dystrophy and other disorders, today announced that Linda Marbán, Ph.D., its president and chief executive officer, is scheduled to present at the 2017 BIO International Convention, in Company Presentation Theater 4, on June 19, 2017 at 3:45 p.m. PDT.
Jun 01, 2017 09:00 am ET
Capricor Therapeutics to Present at the LD Micro Invitational Conference on June 6
LOS ANGELES, June 1, 2017 /PRNewswire/ -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing biological therapies for Duchenne muscular dystrophy and other disorders, today announced that Linda Marbán, Ph.D, president and chief executive officer, is scheduled to present at the LD Micro Invitational Conference on Tuesday, June 6, 2017, at 5:00 pm Pacific Time. The event will be held at the Luxe Sunset Hotel in Bel Air, California.
May 31, 2017 08:00 am ET
Capricor Therapeutics Announces Upcoming Events in Duchenne Muscular Dystrophy Program
LOS ANGELES, May 31, 2017 /PRNewswire/ -- Capricor Therapeutics, Inc. (NASDAQ: CAPR) today announced that a formal meeting between Capricor and the U.S. Food and Drug Administration (FDA), at which Capricor plans to discuss potential product registration strategies for CAP-1002 (allogeneic cardiosphere-derived cells) in the Duchenne muscular dystrophy (DMD) indication, is scheduled to be held by telephone in the second half of June 2017. Capricor also announced today that it will deliver a presentation on its DMD therapeutic development program at the Parent Project Muscular Dystrophy (PPMD)

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.